and has been licensed since 1997 for the treatment of several types of non-Hodgkin lymphoma, including follicular lymphoma, previously untreated diffuse large B-cell lymphoma and chronic ...

About one-fifth of new cases of non-Hodgkin lymphoma are diagnosed as follicular lymphoma 1 ... rituximab improved the survival outlook for these patients. One study showed that after a median ...

A California-based research team examined the possible association between survival and a polygenic risk score comprised of susceptibility loci correlated with follicular lymphoma risk.

The incidence of non-Hodgkin’s lymphoma (NHL) is increasing among ... characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients ...

For slow-growing lymphomas, long-term survival ... growing follicular lymphoma The often more aggressive diffuse large B-cell lymphoma For decades, treatments for non-Hodgkin's lymphoma remained ...

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory follicular lymphoma Compared to placebo, the ...

Follicular lymphoma is the second most common form of non-Hodgkin lymphoma (NHL), and is ... and it has a five-year survival rate of only 20% for patients in the third line and later.

“Non-Hodgkin’s lymphoma is a general category of lymphoma. Many sub-types fall into this category. Diffuse large B-cell lymphoma and follicular ... the 80-90 per cent survival rates seen ...

Follicular lymphoma is the most common indolent form of B-cell non-Hodgkin lymphoma (NHL), accounting ... median investigator-assessed progression-free survival (PFS), of Monjuvi + Rituxan ...

For the follicular lymphoma trial, patients receiving loncastuximab and rituximab had a 67% complete response rate, meaning their cancer could no longer be detected by imaging, and an overall ...